Andrew M. Dahl has sold EW and made no open-market buys since May 2026

Dahl Andrew M. (Andrew M. Dahl) is a Senior Vice President, Corporate Controller and Principal Accounting Officer at Edwards Lifesciences Corporation, a global leader in patient-focused medical innovations.( He joined Edwards in February 2024 as Corporate Controller and, following an announced succession, assumed the role of Principal Accounting Officer effective July 1, 2024, succeeding Robert W.A. Sellers.( Public filings and executive directories describe him as responsible for Edwards’ accounting, financial reporting, and related control functions at the corporate level.(

Before joining Edwards Lifesciences, Dahl held positions of increasing responsibility in finance and accounting at prior employers (as noted in Edwards’ management change disclosures), building a career focused on controllership and corporate accounting leadership.( He holds an undergraduate degree from the University of San Diego, providing the academic foundation for his progression into senior finance and accounting roles.( As a named corporate insider at Edwards, he is reported in regulatory and market databases as Chief Accounting Officer & SVP-Controller and has been associated with equity transactions in Edwards Lifesciences stock in connection with his executive position.(

Written by Perplexity from public sources.